This special issue is devoted to the changing role of pathology in the context of cancer and its treatment with new drugs such as inhibitors of tyrosine kinases, small molecules and antibodies, as well as combination therapies. The analysis of tissues under combined therapy will be a challenge as diff erent changes will intermingle. A further challenge will be the analysis of follow-up biopsies of the same tumor or of secondary tumors following treatment. In future, pathologists are therefore likely to assume a much more active role in the management of cancer, moving from the position of an observer and describer to that of someone who can suggest modalities of personalized therapy based on the functional properties of the cancer cells under scrutiny. New approaches to treat leukemia, lymphoma, skin, breast, kidney and gastrointestinal cancer are discussed in this issue, which is recommended reading to anyone interested in the pathology of cancers under new treatment options.
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Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to 'Oncology' online. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www. karger.com/ocl, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact: 
Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Oncology' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.
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Ethical and Legal Prerequisites
Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983 , 1989 , and 1996 [JAMA 1997 277:925-926] . Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.
Categories of Manuscripts
Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges.
The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.
Clinical Studies and Clinical Translational Research
Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).
Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.
Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a 'positive result' , but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.
Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.
Editorials provide comments on papers published in Oncology. They are usually invited by the Editor.
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Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.
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From Basic Research to Personalised Cancer Treatment
Focusing on the latest developments in basic and discoverydriven translational research through to personalised cancer treatment, EACR-22 will provide a unique forum for discussion between scientists working in all fi elds of cancer research.
For full programme details and to register before regular rate registration closes on 30 May 2012, visit: www.ecco-org.eu/EACR Join us in Barcelona, 7-10 July, 2012 and be inspired by colleagues from around the world.
